Kobo Biotech share price
BSE: 531541Chemicals & PetrochemicalsSmall Cap
KOBO BIOTECH LIMITED · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Mar 2000
Last close ₹3.94down ₹0.08 (1.99%)
Share price at the BSE close on 28 Oct 2026. Previous close ₹4.02.
28 Oct: open ₹3.94, high ₹3.94, low ₹3.94
52-week range of traded prices to 28 Oct 2026
₹1.99Low, 11 Dec 2025₹9.99High, 20 Jul 2026
- Under BSE's graded surveillance, stage 0, on the list for 27 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹9.39 Cr4,799th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- No recent results
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- No recent results
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 3,163
Results
Standalone; ₹ crore.Kobo Biotech quarterly results
Quarter to Jun 2024, against the quarter before
- RevenueRevenue. Under it, revenue in the quarter before. A change in per cent is not worked out where either period is a loss or nothing.
- ₹0.00 CrQuarter to Mar 2024: ₹0.00 Cr
- Net profitNet profit. Under it, net profit in the quarter before. A change in per cent is not worked out where either period is a loss or nothing. Net profit in the glossary
- −₹1.33 CrQuarter to Mar 2024: −₹1.26 Cr
Revenue by quarter
Peak revenue ₹0.00 Cr, quarter to Sep 2022
Net profit by quarter, a loss in red
- Net profit
- Loss
A loss in 8 of the 8 quarters shown
| ₹ crore | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net profit | −1.10 | −1.19 | −1.79 | −1.23 | −1.22 | −1.23 | −1.26 | −1.33 |
Standalone. The last eight quarters. The latest is shaded.
Year to Mar 2024, against the year before
- RevenueRevenue. Under it, revenue in the year before. A change in per cent is not worked out where either period is a loss or nothing.
- ₹0.00 CrYear to Mar 2023: ₹0.00 Cr
- Net profitNet profit. Under it, net profit in the year before. A change in per cent is not worked out where either period is a loss or nothing.
- −₹4.93 CrYear to Mar 2023: −₹5.55 Cr
Revenue by year
Peak revenue ₹29 Cr, year to Mar 2015; lowest ₹0.00 Cr, year to Mar 2019
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 9 of the 9 years with results on record
| ₹ crore | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 29.1 | – | 6.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net profit | −30.3 | – | −19.2 | −23.9 | −24.5 | −21.0 | −19.2 | −15.2 | −5.6 | −4.9 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary | −104.1% | – | −320.9% | −59,810.0% | – | – | – | – | – | – |
Standalone. Years to March. The latest is shaded. No results on record for the year to Mar 2016.
Business segments
In the year to Mar 2024 the company reports one business segment, Manufacturing Active Pharmaceutical Ingredients (API)/ Bulk Drugs, which carries all its revenue.
Where the return came from
Yearly rates to Mar 2024, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +100.0% | – | – | 0.0% |
| 3 years | −19.9% | – | – | 0.0% |
| 5 years | −3.7% | – | – | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record. Earnings growth over 1, 3 and 5 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Kobo Biotech competitors and peers
Commodity Chemicals, 74 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to Kobo Biotech in market cap. 2 companies in the table last traded before then: their rows are priced on their last trade.Chemical companies
Kobo Biotech is not on the chart: it has no P/E or return on equity today
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Square Four Projects IndiaSFPIL | 14 | – | 0.75 | – | – | −1.5% | −1.3% | 0.00% |
 Emmessar Biotech & NutritionEMMESSA | 11 | 28.68 | 1.40 | −46.0% | −0.6% | 5.0% | −18.8% | 0.00% |
 Link Pharma ChemLINKPH | 11 | – | 0.84 | +16.3% | – | −0.1% | 1.2% | 0.00% |
 Sree chem ResinsSRECR | 10 | 233.01 | 0.71 | −15.5% | – | 0.3% | −1.1% | 0.00% |
 Kuwer IndustriesKUWERIN | 9 | – | 0.46 | +34.8% | – | – | −6.2% | 0.00% |
 Lime ChemicalsLIMECHM | 8 | – | 4.71 | +35.5% | – | – | −3.0% | 0.00% |
 Bhagwati OxygenBHAGWOX | 8 | 2.71 | 1.11 | −34.4% | – | 53.0% | −17.2% | 0.00% |
 Omkar PharmachemOMKARPH | 7 | 77.77 | 0.18 | −22.2% | −52.3% | 0.4% | 0.3% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Kobo Biotech dividend history
| Ex-date | Type | Per share |
|---|---|---|
| 21 Sep 2012 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹1.00 |
| 22 Jul 2011 | Final | ₹1.00 |
| 23 Sep 2010 | Final | ₹1.00 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Kobo Biotech announcements
Oct 2026
24 Oct · Management
Jul 2026
24 Jul · Meeting
16 Jul · Update On Implementation Of Approved Resolution Plan Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Kobo Biotech share price by year
Each calendar year to 2025.Kobo Biotech share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 2.39 | −44.9% | 4.13 | 2.09 |
| 2024 | 4.34 | +40.0% | 5.73 | 2.74 |
| 2023 | 3.10 | −16.7% | 4.29 | 1.90 |
| 2022 | 3.72 | −64.0% | 11.32 | 3.48 |
| 2021 | 10.33 | +18.3% | 10.33 | 3.51 |
| 2020 | 8.73 | +164.5% | 10.29 | 1.90 |
| 2019 | 3.30 | −52.8% | 7.00 | 1.25 |
| 2018 | 6.99 | −50.9% | 20.26 | 4.60 |
| 2017 | 14.25 | +24.7% | 14.25 | 4.45 |
| 2016 | 11.43 | −70.4% | 43.30 | 6.61 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The 9 trading days to 27 Oct 2026, as traded on BSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 27 Oct 2026 | 4.00 | 4.02 | 4.00 | 4.02 | 4.02 | 5,423 |
| 26 Oct 2026 | 4.02 | 4.02 | 4.02 | 4.02 | 4.02 | 50 |
| 23 Oct 2026 | 4.10 | 4.10 | 4.10 | 4.10 | 4.10 | 7,436 |
| 22 Oct 2026 | 4.11 | 4.11 | 4.11 | 4.11 | 4.11 | 2,563 |
| 21 Oct 2026 | 4.19 | 4.19 | 4.19 | 4.19 | 4.19 | 4,111 |
| 19 Oct 2026 | 4.27 | 4.27 | 4.27 | 4.27 | 4.27 | 110 |
| 16 Oct 2026 | 4.35 | 4.36 | 4.35 | 4.35 | 4.35 | 9,716 |
| 15 Oct 2026 | 4.43 | 4.47 | 4.43 | 4.43 | 4.43 | 6,970 |
| 14 Oct 2026 | 4.52 | 4.70 | 4.52 | 4.52 | 4.56 | 6,316 |
Prices in ₹ per share as traded, not adjusted.
Company details
- BSE code
- 531541
- ISIN
- INE881A01015
- Industry
- Chemicals & Petrochemicals
- CIN
- L24110TG1993PLC016112
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1993
- Registered office
- Plot No. 121A/ 1, Western Hills, Addagutta Society, Opp. JNTU, Kukatpally, Hyderabad 500072, Telangana
- Share registrar
- XL Softech Systems Ltd
- Keeps the register of shareholders and handles transfers and dividend payments